AnodyneWiki

Trimipramine

Trimipramine
Trimipramine
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass294.40 g/mol [1]
Melting point45 °C [1]
SolubilitySlightly soluble [1]
Predicted LogP5.8 [1]
Structural Identifiers
[]
Molecular formulaC20H26N2
IUPAC name3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine
SMILESCC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C
InChIInChI=1S/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H3
InChIKeyZSCDBOWYZJWBIY-UHFFFAOYSA-N
CAS number3564-75-8
UNIIQJ9MUH57H8
PubChem CID5584
Pharmacokinetics[]
Elimination half-life23–24 hours
MetabolismHepatic
ExcretionRenal
Routes of administrationOral, intramuscular injection, intravenous

Trimipramine (also known as Trimeprimine, Trimeproprimine, Sapilent, β-Methylimipramine, Trimeprimina, Trimipramina, Trimipraminum, 7162 rp, Il 6001 or Il-6001) is a substance of the aniline class.

Chemistry

 []

Trimipramine is a racemic mixture of the (optical activity ( + )).

Stereoisomers from PubChem

Trimipramine matches Lipinski's rule of five (violations: 1).

Pharmacology

Mechanism of action []

Trimipramine's mechanism of action differs from other tricyclic antidepressants. Trimipramine acts by decreasing the reuptake of norepinephrine and serotonin (5-HT). [1]

Interactions []

Interaction mechanisms documented in (number of interacting drugs):

shared target22
shared target19

Medical side effects []

86 side effects listed on drug labels in (trimipramine).

  • Abdominal pain
  • Lymphadenitis
  • Agranulocytosis
  • Alopecia
  • Decreased appetite
  • Anxiety
  • Arrhythmia
  • Asthenia
  • Fatigue
  • Ataxia
  • Confusional state
  • Feeling abnormal
  • Malaise
  • Constipation
  • Libido decreased
  • Disturbance in sexual arousal
  • Delusion
  • Diarrhoea
  • Dizziness
  • Somnolence
  • Oedema
  • Eosinophilia
  • Dermatitis
  • Rash
  • Body temperature increased
  • Flushing
  • Gynaecomastia
  • Hallucination
  • Headache
  • Atrioventricular block
  • Hypertension
  • Hypotension
  • Inappropriate antidiuretic hormone secretion
  • Jaundice
  • Mydriasis
  • Myocardial infarction
  • Acute coronary syndrome
  • Nausea
  • Nightmare
  • Hypoaesthesia
  • Sensory loss
  • Palpitations
  • Ileus paralytic
  • Neuropathy peripheral
  • Petechiae
  • Pruritus
  • Psychotic disorder
  • Purpura
  • Vascular purpura
  • Convulsion
  • Stomatitis
  • Cerebrovascular accident
  • Tachycardia
  • Thrombocytopenia
  • Tinnitus
  • Tremor
  • Pollakiuria
  • Urticaria
  • Vomiting
  • Weight increased
  • Dry mouth
  • Urinary retention
  • Agitation
  • Drug withdrawal syndrome
  • Pancytopenia
  • Accommodation disorder
  • Dyspepsia
  • Discomfort
  • Ill-defined disorder
  • Disorientation
  • Extrapyramidal disorder
  • Dysgeusia
  • Tongue discolouration
  • Galactorrhoea
  • Paraesthesia
  • Tingling sensation
  • Hypomania
  • Erectile dysfunction
  • Oropharyngeal discomfort
  • Oropharyngeal pain
  • Vision blurred
  • Parotid gland enlargement
  • Coordination abnormal
  • Insomnia
  • Breast enlargement
  • Testicular swelling

Indications

  • Depressive symptom
  • Endogenous depression

Subjective effects []

emily / Trimipramine []
Routes:
  • Oral (25 - 30mg)

 []

  • Australia: Trimipramine is a Schedule 4.
  • Brazil: Trimipramine is a C1.[3]
  • Canada: Trimipramine is Prescription only.
  • United Kingdom: Trimipramine is Prescription only.
  • United States: Trimipramine is Prescription only.

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 5584, Trimipramine. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/5584
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Trimipramine. UNII: QJ9MUH57H8. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/QJ9MUH57H8
  3. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-03-31. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 10:31:10
drugspromissing (no DrugsPRO reagent data)2026-11-20 10:31:06
erowidmissing (no Erowid substance of that name)2026-11-20 10:31:06
gsrsok2026-11-20 10:31:06
hmdbmissing (hmdb.ca refused automated access to HMDB0014864)2026-11-20 10:31:06
keggok2026-11-20 10:31:09
pubchemok2026-11-20 10:31:04
redditmissing (no r/tripreports posts mention it)2026-11-20 10:31:06
siderok2026-11-20 10:31:06
structureok2026-11-20 10:31:06
wikipediaok2026-11-20 10:31:06